DE2338350A1 - Beta-(3,4-dialkanoyloxyphenyl)-lalanin-ester - Google Patents
Beta-(3,4-dialkanoyloxyphenyl)-lalanin-esterInfo
- Publication number
- DE2338350A1 DE2338350A1 DE19732338350 DE2338350A DE2338350A1 DE 2338350 A1 DE2338350 A1 DE 2338350A1 DE 19732338350 DE19732338350 DE 19732338350 DE 2338350 A DE2338350 A DE 2338350A DE 2338350 A1 DE2338350 A1 DE 2338350A1
- Authority
- DE
- Germany
- Prior art keywords
- alanine
- meanings
- coor
- zero
- toxic organic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002148 esters Chemical class 0.000 title description 2
- 229960003767 alanine Drugs 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 11
- -1 acetyl halide Chemical class 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 125000004494 ethyl ester group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 231100000252 nontoxic Toxicity 0.000 claims description 8
- 230000003000 nontoxic effect Effects 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 150000007522 mineralic acids Chemical class 0.000 claims description 6
- 150000007524 organic acids Chemical class 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 229960000583 acetic acid Drugs 0.000 claims description 4
- 239000012362 glacial acetic acid Substances 0.000 claims description 4
- 239000011541 reaction mixture Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000003840 hydrochlorides Chemical class 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 4
- 239000012346 acetyl chloride Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000978776 Senegalia senegal Species 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 206010001387 Adrenergic syndrome Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2779772 | 1972-08-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2338350A1 true DE2338350A1 (de) | 1974-02-14 |
Family
ID=11222348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19732338350 Pending DE2338350A1 (de) | 1972-08-02 | 1973-07-27 | Beta-(3,4-dialkanoyloxyphenyl)-lalanin-ester |
Country Status (11)
| Country | Link |
|---|---|
| JP (1) | JPS5029527A (enExample) |
| AU (1) | AU5841773A (enExample) |
| BE (1) | BE803153A (enExample) |
| DD (1) | DD108978A5 (enExample) |
| DE (1) | DE2338350A1 (enExample) |
| ES (1) | ES416936A1 (enExample) |
| FR (1) | FR2194441A1 (enExample) |
| LU (1) | LU68038A1 (enExample) |
| NL (1) | NL7310640A (enExample) |
| SU (1) | SU486505A3 (enExample) |
| ZA (1) | ZA734698B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2994453A4 (en) * | 2013-03-15 | 2017-04-12 | Techfields Pharma Co., Ltd. | Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12013501117A1 (en) | 2010-12-02 | 2013-07-22 | Ono Pharmaceutical Co | Novel compound and medical use thereof |
| JP6987104B2 (ja) * | 2017-12-28 | 2021-12-22 | テックフィールズ ファーマ カンパニー リミテッド | パ−キンソン病治療用の新規高透過薬物及びその組成物 |
| JP6596483B2 (ja) * | 2017-12-28 | 2019-10-23 | テックフィールズ ファーマ カンパニー リミテッド | パ−キンソン病治療用の新規高透過薬物及びその組成物 |
-
1973
- 1973-07-11 ZA ZA734698A patent/ZA734698B/xx unknown
- 1973-07-16 ES ES416936A patent/ES416936A1/es not_active Expired
- 1973-07-18 LU LU68038D patent/LU68038A1/xx unknown
- 1973-07-24 AU AU58417/73A patent/AU5841773A/en not_active Expired
- 1973-07-27 DE DE19732338350 patent/DE2338350A1/de active Pending
- 1973-07-31 FR FR7328009A patent/FR2194441A1/fr not_active Withdrawn
- 1973-08-01 JP JP8589273A patent/JPS5029527A/ja active Pending
- 1973-08-01 SU SU1956140A patent/SU486505A3/ru active
- 1973-08-01 DD DD17266573A patent/DD108978A5/xx unknown
- 1973-08-01 NL NL7310640A patent/NL7310640A/xx unknown
- 1973-08-02 BE BE134182A patent/BE803153A/xx unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2994453A4 (en) * | 2013-03-15 | 2017-04-12 | Techfields Pharma Co., Ltd. | Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases |
| US9718766B2 (en) | 2013-03-15 | 2017-08-01 | Techfields Pharma Co., Ltd. | High penetration drugs and their compositions thereof for treatment of parkinson diseases |
| US11084813B2 (en) | 2013-03-15 | 2021-08-10 | Techfields Pharma Co., Ltd. | High penetration drugs and their compositions thereof for treatment of Parkinson diseases |
| US11685739B2 (en) | 2013-03-15 | 2023-06-27 | Techfields Pharma Co., Ltd. | High penetration drugs and their compositions thereof for treatment of Parkinson diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA734698B (en) | 1974-06-26 |
| NL7310640A (enExample) | 1974-02-05 |
| DD108978A5 (enExample) | 1974-10-12 |
| AU5841773A (en) | 1975-01-30 |
| SU486505A3 (ru) | 1975-09-30 |
| ES416936A1 (es) | 1976-03-01 |
| JPS5029527A (enExample) | 1975-03-25 |
| FR2194441A1 (en) | 1974-03-01 |
| BE803153A (fr) | 1973-12-03 |
| LU68038A1 (enExample) | 1973-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2065635C3 (de) | 10-Dioxo-11 -methyldibenzothiazepinderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen | |
| DE2451161A1 (de) | Stabile prostaglandin-e-gruppen enthaltende arzneimittelzubereitung sowie verfahren zu deren herstellung | |
| DE3335891A1 (de) | 2,5-piperazindionderivate, ihre herstellung und ihre pharmazeutische verwendung | |
| DE2446100C3 (de) | Phenoxyalkancarbonsäureamide von Thiazolidincarbonsäuren, Verfahren zu ihrer Herstellung und Arzneimittel | |
| DE2338350A1 (de) | Beta-(3,4-dialkanoyloxyphenyl)-lalanin-ester | |
| DE2729414A1 (de) | Thiazolidincarbonsaeurederivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| DE2413125C2 (de) | Indolylacetylaminosäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneipräparate | |
| DE69217087T2 (de) | Indolderivat mit verlängerter immunostimmulierender wirkung und pharmazeutische zusammensetzungen daraus | |
| DE2036935A1 (de) | Verfahren zur Herstellung von Isoniazid derivaten | |
| DE2655130C3 (de) | Eine praktisch lösungsmittelfreie Kristallform des Cefacetril-Natriumsalzes | |
| DE1965343A1 (de) | Arzneimittel,insbesondere zur Herabsetzung der Schleimviskositaet und Anwendung als hustenstillendes Mittel,und Verfahren zu seiner Herstellung | |
| DE1493618A1 (de) | Cumarinderivate und ein Verfahren zu ihrer Herstellung | |
| DE2264938A1 (de) | 3-arylaminocarbonyl-4-hydroxy-benzo eckige klammer auf b eckige klammer zu thiacyclohex(3)en-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel | |
| DE2615129C3 (de) | Tripeptide, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen | |
| DE2213028B2 (de) | Dl-3-formylaminothiacyclopentan-2- on-, verfahren zu dessen herstellung und dl-3-formylamino-thiacyclopentan-2-on und andere acylderivate enthaltende pharmazeutische zusammensetzungen | |
| DE2327192C2 (de) | Verfahren zur Herstellung von N-(Diethylaminoethyl)-2-methoxy-5-methylsulfonylbenzamid und seinen Additionssalzen | |
| DE2166270B2 (de) | Nicotinoylaminoäthansulfonyl-2amino-thiazol | |
| DE2327193C3 (de) | N-(Diethylaminoethyl)-2-methoxy-5methylsulfonylbenzamid, seine Salze, Verfahren zur Herstellung dieser Verbindungen sowie diese Verbindungen enthaltende Arzneimittel | |
| DE2164988C3 (de) | 2,2-Diphenylcyclopropancarbonsäureesterderivate, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel | |
| DE2042637C3 (de) | D-6-Methyl-8-ergoIin-(l)-yl-essigsäureamid, seine Salze sowie pharmazeutische Mittel | |
| DE2221281A1 (de) | Pyrazolderivate und Verfahren zu ihrer Herstellung | |
| DE2523208C3 (de) | Thienylessigsäureester, ein Verfahren zu ihrer Herstellung sowie Arzneimittel | |
| DE2226298C3 (de) | 3-Arylaminocarbonyl-4-hydroxybenzo eckige Klammer auf b eckige Klammer zu thiacyclohex(3)en-1,1-dioxide, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| DE1620195C (de) | Optisch aktive und racemische Berbin derivate und em Verfahren zu ihrer Her stellung Ausscheidung aus 1620172 | |
| DE2316914C3 (de) | 4-(p-Chlorphenoxyacetylamino) benzoesäurediäthylamino-äthylester-pchlorphenoxyisobutyrat Verfahren zu seiner Herstellung und diese Verbindung enthaltende Arzneimittel |